Every 10-Q that Omnicell Inc (OMCL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OMCL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMCL filings page.
Omnicell, Inc. reported stronger results for the quarter and six months ended June 30, 2026. Second‑quarter total revenue was $312.2 million, up from $290.6 million a year earlier, with growth in both product and service lines. First‑half revenue reached $622.1 million versus $560.2 million in 2025.
Quarterly net income was $24.3 million (diluted EPS $0.52), compared with $5.6 million (EPS $0.12) last year; for the first half, net income was $35.6 million versus a prior‑year loss of $1.4 million. Gross profit increased to $152.9 million in Q2, aided by lower product costs, including a $14.5 million refund of previously paid tariffs recorded primarily as a reduction of cost of product revenues.
Operating cash flow for the first six months rose to $122.8 million from $68.7 million, supporting cash and cash equivalents of $292.2 million at June 30, 2026. Total assets were $2.0 billion, stockholders’ equity $1.29 billion, and the company had $172.5 million principal of 1.00% convertible senior notes due 2029 outstanding, while its $350 million revolving credit facility remained fully available.
Omnicell, Inc. reported stronger results for the three months ended March 31, 2026, with total revenues of $309.9 million compared to $269.7 million a year earlier, driven by growth in both product and service revenues. Net income was $11.4 million, versus a net loss of $7.0 million in the prior-year period, and diluted earnings per share reached $0.25.
Operating cash flow increased to $54.5 million from $25.9 million, supporting a cash, cash equivalents, and restricted cash balance of $291.0 million and total assets of $2.0 billion. The company ended the quarter with no borrowings under its $350.0 million revolving credit facility and had $172.5 million of 1.00% Convertible Senior Notes due 2029 outstanding.
Omnicell reported Q3 2025 results, with total revenue of $310.6 million, up from $282.4 million a year ago. Product revenue was $177.5 million and service revenue was $133.1 million. Net income was $5.5 million, or $0.12 per diluted share, versus $8.6 million, or $0.19, last year as operating expenses rose.
For the first nine months, revenue reached $870.9 million with net income of $4.1 million. Cash from operations was $96.9 million. The company ended the quarter with $180.1 million in cash and cash equivalents. Omnicell repaid the remaining $175.0 million principal of its 0.25% convertible notes due 2025 and had $167.3 million (net) outstanding on the 1.00% notes due 2029. Deferred revenues were $245.5 million, including $178.8 million current.
Stockholders’ equity was $1.22 billion. The company repurchased common stock totaling $77.6 million year‑to‑date, and shares outstanding were 44,876,522 as of October 29, 2025.